Pfizer recently reported positive Phase 2b results for its monthly injectable obesity drug PF-3944, showing up to 12.3% ...
PFE stock today: Pfizer's stock dipped despite strong fourth-quarter earnings. Investors reacted to the company's modest 2026 outlook. Declining Covid product sales and patent expirations are key ...
One of the latest voices weighing in is Jason Gerberry of Bank of America, who reiterated a Hold (Neutral) stance on Pfizer on February 4, 2026, setting a price objective of $27.00. This target sits ...
TipRanks Ranking Metrics: This 4-star analyst ranks #324 out of 11,984, with a 61.73% success rate and a 15.50% average return per rating. Investors tracking Gerberry’s calls may appreciate his ...
Zacks.com on MSN
PowerFleet (AIOT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
Wall Street expects a year-over-year increase in earnings on higher revenues when PowerFleet (AIOT) reports results for the quarter ended December 2025. While this widely-known consensus outlook is ...
Pfizer Inc. (PFE) shares are trading higher on Tuesday, as the stock benefits from a price target increase at Cantor ...
Zacks Investment Research on MSN
Ahead of Pfizer (PFE) Q4 earnings: Get ready with Wall Street estimates for key metrics
In its upcoming report, Pfizer (PFE) is predicted by Wall Street analysts to post quarterly earnings of $0.57 per share, reflecting a decline of 9.5% compared to the same period last year. Revenues ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results